PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23877009-9	2013	Exposure of PX-866 treated cells to sorafenib reduced p62 and LAMP2 levels, decreased the ratio of LC3 to LC3II, and reduced LC3-GFP vesicle levels.	Sorafenib	36-45	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102	
26505133-5	2015	Mechanistically, in the presence of metformin, the anticancer potential of sorafenib, accompanying with increased LC3 levels, is found to be synergistically enhanced with the remarkably reduced protein expression of the mTOR/p70S6K/4EBP1 pathway, while not appreciably altering cell cycle.	Sorafenib	75-84	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	114-117	
23877009-9	2013	Exposure of PX-866 treated cells to sorafenib reduced p62 and LAMP2 levels, decreased the ratio of LC3 to LC3II, and reduced LC3-GFP vesicle levels.	Sorafenib	36-45	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	106-109	
33112540-7	2020	qPCR and western blot revealed that a combination of Sorafenib (10 mumol/L) and cisplatinum (10 mg/L) reduced the transcription and protein expression of autophagy-related AKT and mTOR but increased that of LC3 (P <0.05).	Sorafenib	53-62	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	207-210